Researchers at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT have engineered changes to the revolutionary CRISPR-Cas9 genome editing system that significantly cut down on “off-target” editing errors. The refined technique addresses one of the major technical issues in the use of genome editing.
The CRISPR-Cas9 system works by making a precisely targeted modification in a cell’s DNA. The protein Cas9 alters the DNA at a location that is specified by a short RNA whose sequence matches that of the target site. While Cas9 is known to be highly efficient at cutting its target site, a major drawback of the system has been that, once inside a cell, it can bind to and cut additional sites that are not targeted. This has the potential to produce undesired edits that can alter gene expression or knock a gene out entirely, which might lead to the development of cancer or other problems. In a paper published today in Science, Feng Zhang and his colleagues report that changing three of the approximately 1,400 amino acids that make up the Cas9 enzyme from S. pyogenes dramatically reduced “off-target editing” to undetectable levels in the specific cases examined.
Zhang and his colleagues used knowledge about the structure of the Cas9 protein to decrease off-target cutting. DNA, which is negatively charged, binds to a groove in the Cas9 protein that is positively charged. Knowing the structure, the scientists were able to predict that replacing some of the positively charged amino acids with neutral ones would decrease the binding of “off target” sequences much more than “on target” sequences.
After experimenting with various possible changes, Zhang’s team found that mutations in three amino acids dramatically reduced “off-target” cuts. For the guide RNAs tested, “off-target” cutting was so low as to be undetectable.
The newly-engineered enzyme, which the team calls “enhanced” S. pyogenes Cas9, or eSpCas9, will be useful for genome editing applications that require a high level of specificity. The Zhang lab is immediately making the eSpCas9 enzyme available for researchers worldwide. The team believes the same charge-changing approach will work with other recently described RNA-guided DNA targeting enzymes, including Cpf1, C2C1, and C2C3, which Zhang and his collaborators reported on earlier this year.
The prospect of rapid and efficient genome editing raises many ethical and societal concerns, says Zhang, who is speaking this morning at the International Summit on Gene Editing in Washington, DC. “Many of the safety concerns are related to off-target effects,” he said. “We hope the development of eSpCas9 will help address some of those concerns, but we certainly don’t see this as a magic bullet. The field is advancing at a rapid pace, and there is still a lot to learn before we can consider applying this technology for clinical use.”
The Latest on: CRISPR-Cas9 genome editing
via Google News
The Latest on: CRISPR-Cas9 genome editing
- CRISPR-Cas9: The era of genome editingon January 24, 2020 at 6:12 am
Officials in the state of California are worried its use could get out of control. An important application of genome editing is so-called gene drive, which could help put an end to malaria by ...
- Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editingon January 24, 2020 at 5:00 am
As such, major challenges have limited the application of existing technologies in functional analysis of a specific enhancer in a mammalian genome. Reporter assays have historically been ... in the ...
- Single AAV-mediated mutation replacement genome editing in limited number of photoreceptors restores vision in miceon January 24, 2020 at 4:58 am
To overcome this issue, we developed a single AAV platform that allows local replacement of a mutated sequence with its wildtype counterpart, based on combined CRISPR-Cas9 and micro-homology-mediated ...
- CRISPR Has The Potential To Improve Lives. But At What Cost?on January 22, 2020 at 9:30 pm
"In November 2018, at the Second International Summit on Human Genome Editing in Hong Kong, scientist He Jiankui announced that he had broken the basic medical mantra of 'do no harm' by using ...
- Companies Join Forces to Address Urgently Needed Quality Control of CRISPR Genome-editingon January 21, 2020 at 4:17 am
The company supports customers globally with detailed DNA mutation analysis and complexed protein expression profiling of cells, plants or animals modified with genome editing tools such as ...
- Genome Editing Market Share Growing Rapidly with Recent Trends, Revenue and Forecast to 2025on January 20, 2020 at 9:35 am
New York, January 20, 2020: Global Genome Editing Market is expected to exceed more than US$ 7.5 billion by 2024 at CAGR of 14% in the given forecast period. Browse Full Report: ...
- Algentech Granted US Patent For A Key Genome Editing Technologyon January 20, 2020 at 5:15 am
/PRNewswire/ -- ALGENTECH, announces the issuance of a key patent in the field of genome editing by the U.S. Patent Office (U.S. patent number 10457950).
- New tumor-driving mutations discovered in the under-explored regions of the cancer genomeon January 18, 2020 at 1:51 am
The group performed CRISPR-Cas9 genome editing and functional experiments in human cell lines to explore the cancer-driving properties of this non-coding region. "We characterized several non ...
- New tumour-driving mutations discovered in the under-explored regions of the cancer genomeon January 17, 2020 at 1:49 pm
The group performed CRISPR-Cas9 genome editing and functional experiments in human cell lines to explore the cancer-driving properties of this non-coding region. "We characterized several non-coding ...
- Study looks to genome editing to treat deadly degenerative disorderon January 13, 2020 at 10:24 am
Combining cutting-edge CRISPR/Cas9 genome-editing technologies with a deep knowledge of stem-cell science and regenerative biology, this approach if successful might offer a permanent restoration of ...
via Bing News